Advertisement
New Zealand markets closed

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NZD/USD

    0.5954
    +0.0004 (+0.07%)
     

  • NZD/EUR

    0.5554
    +0.0014 (+0.25%)
     

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • OIL

    84.15
    +0.58 (+0.69%)
     

  • GOLD

    2,359.10
    +16.60 (+0.71%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,117.58
    +38.72 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,069.75
    +152.47 (+0.85%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • NZD/JPY

    93.3350
    +0.8390 (+0.91%)
     

The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer

David Jagielski, The Motley Fool
·4-min read
The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer

Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are two healthcare companies aiming to produce a vaccine for the respiratory syncytial virus (RSV). In trials, their vaccine candidates have been proving highly effective, and it may not be long before these COVID-19 vaccine makers are fighting for market share again -- this time in the RSV market. The Food and Drug Administration (FDA) recently approved an RSV vaccine, and it wasn't from either of these two companies.

Continue reading